Company profile: OncoSec
1.1 - Company Overview
Company description
- Provider of oncology gene therapies and delivery technologies using electroporation to create transient cell membrane pores for improved IL-12 uptake. Offers TAVO (tavokinogene telseplasmid) intratumoral IL-12 therapy, Visceral Lesion Applicator for internal tumors, a plasmid DNA delivery platform, clinical trials to advance its technology, and global partnerships.
Products and services
- Electroporation (EP) Gene Delivery: Short-duration electrical pulse-based system applying short electric impulses to tumors that transiently open cellular membranes, increasing permeability for plasmid DNA and facilitating DNA-based IL-12 uptake into cells
- TAVO (tavokinogene telseplasmid): DNA-based IL-12 therapy administered directly into tumors to stimulate an immune response against cancer, leveraging electroporation to enhance cellular uptake of therapeutic plasmid DNA
- Visceral Lesion Applicator (VLA): Non-cutaneous applicator engineered to deliver immunologically relevant genes directly to internal tumor sites, enabling targeted treatment of visceral lesions by delivering genes directly to the tumor site
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to OncoSec
ImmunoGenesis
HQ: United States
Website
- Description: Provider of immune therapies for tumor treatment, including IMGS-001, a dual-specific PD-L1/PD-L2 inhibitor with cytotoxic effector function for immune-excluded tumors resistant to immunotherapies; IMGS-501, an antibody-conjugated STING agonist delivered via PD-L1/PD-L2 targeting to tumor sites; and IMGS-101, a hypoxia-reversal agent that reoxygenates the tumor microenvironment to enable T-cell access.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full ImmunoGenesis company profile →
Novavax
HQ: United States
Website
- Description: Provider of vaccines and vaccine technologies for infectious diseases, including a recombinant nanoparticle COVID-19 vaccine with Matrix-M adjuvant; a Phase 2 COVID-influenza combination (CIC) vaccine; and the authorized R21/Matrix-M malaria vaccine. Also offers Matrix-M, a saponin-based adjuvant, and recombinant nanoparticle vaccine technology using engineered proteins.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Novavax company profile →
Replimune
HQ: United States
Website
- Description: Provider of next-generation oncolytic immunotherapies for cancer, developing proprietary products that enhance direct anti-tumor effects of selective virus replication and boost immune responses to tumor antigens. Products include RP1 (HSV-1 strain with immune-activating transgenes), RP2 (anti-CTLA-4 antibody targeting immunologically silent tumors to enhance tumor killing and immune response), and RP3 (CD40L and 4-1BBL ligands).
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Replimune company profile →
Trellis Bioscience
HQ: United States
Website
- Description: Provider of therapeutic antibody therapies for infectious diseases and oncology, developing TRL1068 to disrupt bacterial biofilms and enhance antibiotics in prosthetic joint infections, TRL404 pan-influenza antibody cocktail, TRL3D3 targeting RSV, and TRL345 against cytomegalovirus, enabled by the CellSpot platform to discover high-affinity monoclonal antibodies from human memory B-cells.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Trellis Bioscience company profile →
Pulmotect
HQ: United States
Website
- Description: Provider of an inhaled therapeutic to prevent and treat respiratory infections. PUL-042 activates the innate immune system in the lungs to protect against viral, bacterial, and fungal pathogens.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Pulmotect company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for OncoSec
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to OncoSec
2.2 - Growth funds investing in similar companies to OncoSec
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for OncoSec
4.2 - Public trading comparable groups for OncoSec
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →